Joshua Coney, MD
Advanced Heart Failure and Transplant Cardiology · Columbia, SCNPI 1376987669
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Cvrx, Inc. at 53.7% of the total. Reporting peaked in 2023 at $8,087 and has fallen 97.2% since, to $226 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in SC, where the typical reported total is $13,902.
Across 139 payments — averaging $100.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$7K
- Abbott$3K
- Medtronic$2K
- Abiomed$315
- Boston Scientific$280
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$245
- plus $992 from 11 others
What the payments were for
- Consulting fees$6,00043%
- Travel & lodging$2,86421%
- Food & beverage$5,03836%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 13 | $7,469 |
| Abbott | 50 | $2,958 |
| Medtronic(2 entities) | 12 | $1,644 |
| Abiomed | 6 | $315 |
| Boston Scientific | 5 | $280 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $245 |
| E.r. Squibb & Sons, L.L.C. | 3 | $150 |
| Pfizer | 3 | $144 |
| Kestra Medical Technology Services, Inc. | 3 | $129 |
| AstraZeneca | 9 | $122 |
| Amarin Pharma, Inc. | 6 | $121 |
| Boehringer Ingelheim | 6 | $106 |
| Merck | 6 | $89 |
| Novartis | 4 | $75 |
| Amgen | 1 | $19 |
| Cordis US CORP. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$7,348
- CARDIOMEMS$1,177
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$424
- Watchman$221
- MitraClip$171
- IN.PACT Admiral$144
- COBALT DR MRI SURESCAN$128
- Cobalt$120
- VYNDAQEL$118
- ELIQUIS$117
- Impella$113
- CentriMag$111
- HeartMate 3 Left Ventricular Dev$109
How this compares
$13,902 in reported general payments places this provider in the 50th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
See all advanced heart failure and transplant cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 168 | $3,810,042 |
| CamzyosMavacamten | 46 | $388,280 |
| EntrestoSacubitril/Valsartan | 222 | $241,897 |
| JardianceEmpagliflozin | 261 | $239,453 |
| EliquisApixaban | 152 | $133,365 |
| FarxigaDapagliflozin Propanediol | 80 | $84,212 |
| Tadalafil | 13 | $33,368 |
| Repatha SureclickEvolocumab | 23 | $26,026 |
| CorlanorIvabradine Hcl | 17 | $12,492 |
| OzempicSemaglutide | 12 | $11,234 |
| Bumetanide | 71 | $4,485 |
| Potassium Chloride | 87 | $3,439 |
| Metoprolol Succinate | 174 | $2,324 |
| Spironolactone | 264 | $2,281 |
| Carvedilol | 185 | $1,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $144 | $3,943,407320 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $150 | $388,28046 claims |
| NovartisEntresto | $75 | $241,897222 claims |
| Boehringer IngelheimJardiance | $106 | $239,453261 claims |
| AstraZenecaFarxiga | $122 | $84,21280 claims |
| AmgenCorlanor | $19 | $12,49217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
Other advanced heart failure and transplant cardiology in Columbia
- Patrick McCannColumbia$579K
- James AmpaduColumbia$131K
- Cassandra Buto-CollettiColumbia$21K
- Barry FeldmanColumbia$12K
- Rebecca NapierColumbia$12K
- Michael RofaelColumbia$11K
- Ryan TedfordCharleston$528K
- Michael ZileCharleston$358K
- Anil PurohitWest Columbia$172K
- Daniel JudgeCharleston$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.